<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>73-APIXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the apixaban by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>73-APIXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the apixiban by the fluconazole, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>73-APIXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the apixaban by the inhibitor, with increase of the risk of bleeding. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>73-APIXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
